Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

TALK vs MNMD vs ATAI vs HIMS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TALK
Talkspace, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$868M
5Y Perf.-37.7%
MNMD
Mind Medicine (MindMed) Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$2.04B
5Y Perf.-63.5%
ATAI
Atai Beckley N.V

Medical - Pharmaceuticals

HealthcareNASDAQ • NL
Market Cap$964M
5Y Perf.-78.3%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.+135.7%

TALK vs MNMD vs ATAI vs HIMS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TALK logoTALK
MNMD logoMNMD
ATAI logoATAI
HIMS logoHIMS
IndustryMedical - Care FacilitiesBiotechnologyMedical - PharmaceuticalsMedical - Equipment & Services
Market Cap$868M$2.04B$964M$6.63B
Revenue (TTM)$229M$0.00$3M$2.35B
Net Income (TTM)$8M$-238M$-154M$128M
Gross Margin43.0%-259.1%69.7%
Operating Margin1.4%-34.6%4.6%
Forward P/E38.2x51.5x
Total Debt$0.00$0.00$25M$1.12B
Cash & Equiv.$37M$258M$18M$229M

TALK vs MNMD vs ATAI vs HIMSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TALK
MNMD
ATAI
HIMS
StockJun 21May 26Return
Talkspace, Inc. (TALK)10062.3-37.7%
Mind Medicine (Mind… (MNMD)10036.5-63.5%
Atai Beckley N.V (ATAI)10021.7-78.3%
Hims & Hers Health,… (HIMS)100235.7+135.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TALK vs MNMD vs ATAI vs HIMS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HIMS leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Talkspace, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. MNMD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
TALK
Talkspace, Inc.
The Income Pick

TALK is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • beta 0.86
  • Lower volatility, beta 0.86, current ratio 6.38x
  • Beta 0.86, current ratio 6.38x
  • Lower P/E (38.2x vs 51.5x)
Best for: income & stability and sleep-well-at-night
MNMD
Mind Medicine (MindMed) Inc.
The Momentum Pick

MNMD is the clearest fit if your priority is momentum.

  • +214.0% vs HIMS's -51.0%
Best for: momentum
ATAI
Atai Beckley N.V
The Secondary Option

ATAI lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
HIMS
Hims & Hers Health, Inc.
The Growth Play

HIMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
  • 161.9% 10Y total return vs MNMD's 5.1%
  • 59.0% revenue growth vs MNMD's -96.9%
  • 5.5% margin vs ATAI's -51.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs MNMD's -96.9%
ValueTALK logoTALKLower P/E (38.2x vs 51.5x)
Quality / MarginsHIMS logoHIMS5.5% margin vs ATAI's -51.1%
Stability / SafetyTALK logoTALKBeta 0.86 vs HIMS's 2.40
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)MNMD logoMNMD+214.0% vs HIMS's -51.0%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs MNMD's -70.7%, ROIC 10.7% vs -389.5%

TALK vs MNMD vs ATAI vs HIMS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TALKTalkspace, Inc.

Segment breakdown not available.

MNMDMind Medicine (MindMed) Inc.

Segment breakdown not available.

ATAIAtai Beckley N.V
FY 2024
Research And Development Services
100.0%$300,000
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

TALK vs MNMD vs ATAI vs HIMS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHIMSLAGGINGATAI

Income & Cash Flow (Last 12 Months)

HIMS leads this category, winning 5 of 6 comparable metrics.

HIMS and MNMD operate at a comparable scale, with $2.3B and $0 in trailing revenue. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to ATAI's -51.1%. On growth, ATAI holds the edge at +17.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTALK logoTALKTalkspace, Inc.MNMD logoMNMDMind Medicine (Mi…ATAI logoATAIAtai Beckley N.VHIMS logoHIMSHims & Hers Healt…
RevenueTrailing 12 months$229M$0$3M$2.3B
EBITDAEarnings before interest/tax$7M-$191M-$103M$164M
Net IncomeAfter-tax profit$8M-$238M-$154M$128M
Free Cash FlowCash after capex-$2M-$174M-$90M$73M
Gross MarginGross profit ÷ Revenue+43.0%-2.6%+69.7%
Operating MarginEBIT ÷ Revenue+1.4%-34.6%+4.6%
Net MarginNet income ÷ Revenue+3.4%-51.1%+5.5%
FCF MarginFCF ÷ Revenue-0.9%-29.9%+3.1%
Rev. Growth (YoY)Latest quarter vs prior year+29.3%+17.7%+28.4%
EPS Growth (YoY)Latest quarter vs prior year-163.0%-75.0%-27.3%
HIMS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

HIMS leads this category, winning 2 of 5 comparable metrics.

At 50.3x trailing earnings, HIMS trades at a 61% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, HIMS's 42.7x EV/EBITDA is more attractive than TALK's 137.8x.

MetricTALK logoTALKTalkspace, Inc.MNMD logoMNMDMind Medicine (Mi…ATAI logoATAIAtai Beckley N.VHIMS logoHIMSHims & Hers Healt…
Market CapShares × price$868M$2.0B$964M$6.6B
Enterprise ValueMkt cap + debt − cash$830M$1.8B$971M$7.5B
Trailing P/EPrice ÷ TTM EPS129.50x-10.04x-4.31x50.32x
Forward P/EPrice ÷ next-FY EPS est.38.20x51.51x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple137.77x42.68x
Price / SalesMarket cap ÷ Revenue3.79x3130.37x2.82x
Price / BookPrice ÷ Book value/share7.69x5.56x5.51x12.25x
Price / FCFMarket cap ÷ FCF89.61x
HIMS leads this category, winning 2 of 5 comparable metrics.

Profitability & Efficiency

HIMS leads this category, winning 4 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-102 for MNMD. ATAI carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), TALK scores 6/9 vs ATAI's 2/9, reflecting solid financial health.

MetricTALK logoTALKTalkspace, Inc.MNMD logoMNMDMind Medicine (Mi…ATAI logoATAIAtai Beckley N.VHIMS logoHIMSHims & Hers Healt…
ROE (TTM)Return on equity+6.9%-102.5%-96.4%+23.7%
ROA (TTM)Return on assets+5.9%-70.7%-64.3%+6.0%
ROICReturn on invested capital+3.9%-3.9%-45.0%+10.7%
ROCEReturn on capital employed+2.7%-52.2%-50.4%+10.9%
Piotroski ScoreFundamental quality 0–96324
Debt / EquityFinancial leverage0.21x2.07x
Net DebtTotal debt minus cash-$37M-$258M$7M$892M
Cash & Equiv.Liquid assets$37M$258M$18M$229M
Total DebtShort + long-term debt$0$0$25M$1.1B
Interest CoverageEBIT ÷ Interest expense-21.81x-68.93x
HIMS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MNMD leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $2,016 for ATAI. Over the past 12 months, MNMD leads with a +214.0% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs ATAI's 25.9% — a key indicator of consistent wealth creation.

MetricTALK logoTALKTalkspace, Inc.MNMD logoMNMDMind Medicine (Mi…ATAI logoATAIAtai Beckley N.VHIMS logoHIMSHims & Hers Healt…
YTD ReturnYear-to-date+47.6%+51.7%+3.6%-23.2%
1-Year ReturnPast 12 months+70.4%+214.0%+188.5%-51.0%
3-Year ReturnCumulative with dividends+490.0%+510.3%+99.5%+116.6%
5-Year ReturnCumulative with dividends-47.7%-57.9%-79.8%+137.6%
10-Year ReturnCumulative with dividends-48.7%+512.1%-47.7%+161.9%
CAGR (3Y)Annualised 3-year return+80.7%+82.7%+25.9%+29.4%
MNMD leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

TALK leads this category, winning 2 of 2 comparable metrics.

TALK is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTALK logoTALKTalkspace, Inc.MNMD logoMNMDMind Medicine (Mi…ATAI logoATAIAtai Beckley N.VHIMS logoHIMSHims & Hers Healt…
Beta (5Y)Sensitivity to S&P 5000.86x1.68x1.48x2.40x
52-Week HighHighest price in past year$5.20$21.09$6.75$70.43
52-Week LowLowest price in past year$2.22$6.03$1.29$13.74
% of 52W HighCurrent price vs 52-week peak+99.6%+98.1%+59.4%+36.4%
RSI (14)Momentum oscillator 0–10062.764.951.554.5
Avg Volume (50D)Average daily shares traded4.5M792K6.0M34.9M
TALK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: TALK as "Hold", MNMD as "Buy", ATAI as "Buy", HIMS as "Hold". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).

MetricTALK logoTALKTalkspace, Inc.MNMD logoMNMDMind Medicine (Mi…ATAI logoATAIAtai Beckley N.VHIMS logoHIMSHims & Hers Healt…
Analyst RatingConsensus buy/hold/sellHoldBuyBuyHold
Price TargetConsensus 12-month target$5.25$20.00$12.00$29.67
# AnalystsCovering analysts101419
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+2.0%0.0%0.0%+1.4%
Insufficient data to determine a leader in this category.
Key Takeaway

HIMS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). MNMD leads in 1 (Total Returns).

Best OverallHims & Hers Health, Inc. (HIMS)Leads 3 of 6 categories
Loading custom metrics...

TALK vs MNMD vs ATAI vs HIMS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TALK or MNMD or ATAI or HIMS a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 9% for Atai Beckley N. V (ATAI). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TALK or MNMD or ATAI or HIMS?

On trailing P/E, Hims & Hers Health, Inc.

(HIMS) is the cheapest at 50. 3x versus Talkspace, Inc. at 129. 5x. On forward P/E, Talkspace, Inc. is actually cheaper at 38. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — TALK or MNMD or ATAI or HIMS?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -79. 8% for Atai Beckley N. V (ATAI). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus TALK's -48. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TALK or MNMD or ATAI or HIMS?

By beta (market sensitivity over 5 years), Talkspace, Inc.

(TALK) is the lower-risk stock at 0. 86β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 179% more volatile than TALK relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 21% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TALK or MNMD or ATAI or HIMS?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -1. 9% for Atai Beckley N. V (ATAI). On earnings-per-share growth, the picture is similar: Hims & Hers Health, Inc. grew EPS -3. 8% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TALK or MNMD or ATAI or HIMS?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TALK or MNMD or ATAI or HIMS more undervalued right now?

On forward earnings alone, Talkspace, Inc.

(TALK) trades at 38. 2x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 13. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATAI: 199. 3% to $12. 00.

08

Which pays a better dividend — TALK or MNMD or ATAI or HIMS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is TALK or MNMD or ATAI or HIMS better for a retirement portfolio?

For long-horizon retirement investors, Talkspace, Inc.

(TALK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TALK: -48. 7%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TALK and MNMD and ATAI and HIMS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TALK is a small-cap high-growth stock; MNMD is a small-cap quality compounder stock; ATAI is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TALK

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Gross Margin > 25%
Run This Screen
Stocks Like

MNMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ATAI

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 886%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.